Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer

Open access
Khan, Zia, Di Nucci, Flavia, Kwan, Antonia, Hammer, Christian, Mariathasan, Sanjeev, Rouilly, Vincent, Carroll, Jonathan, Fontes, Magnus, Ley Acosta, Sergio, Guardino, Ellie, Chen-Harris, Haiyin, Bhangale, Tushar, Mellman, Ira, Rosenberg, Jonathan, Powles, Thomas, Hunkapiller, Julie, Chandler, G. Scott, Albert, Matthew L. · 2020 · Proceedings of the National Academy of Sciences

Published version of a preprint

Abstract

PD-1 and PD-L1 act to restrict T cell responses in cancer and contribute to self-tolerance. Consistent with this role, PD-1 checkpoint inhibitors have been associated with immune-related adverse events (irAEs), immune toxicities thought to be autoimmune in origin. Analyses of dermatological irAEs have identified an association with improved overall survival (OS) following anti-PD-(L)1 therapy, but the factors that contribute to this relationship are poorly understood. We collected germline whole-genome sequencing data from IMvigor211, a recent phase 3 randomized controlled trial comparing atezolizumab (anti-PD-L1) monotherapy to chemotherapy in bladder cancer. We found that high vitiligo, high psoriasis, and low atopic dermatitis polygenic risk scores (PRSs) were associated with longer OS under anti-PD-L1 monotherapy as compared to chemotherapy, reflecting the Th17 polarization of these diseases. PRSs were not correlated with tumor mutation burden, PD-L1 immunohistochemistry, nor T-effector gene signatures. Shared genetic factors impact risk for dermatological autoimmunity and anti-PD-L1 monotherapy in bladder cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1922867117

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Low-grade dermatological irAEs in patients receiving atezolizumab are associated with longer OS. (A) Rate of irAEs, aggregated by system- and organ-based classification, across trials. Only irAE categories with occurrence rates >5% are shown. Low = grade 1 or 2 (orange stacking bar); High = grade 3, 4, or 5 (gray stacking bar). (B) Hazard ratios (HRs) with 95% CIs are shown as thick lines, comparing OS of individuals that experienced low-grade irAEs to those that did not experience irAE of a given classification. Individuals that experienced a high-grade irAE of the given classification were excluded from the analysis. A time-dependent covariate in a Cox proportional hazards model was used to estimate the HRs (see Methods). (C) Distribution of time to first skin irAE in days across trials. Ninety percent of patients that experienced skin irAEs lie to the left of the orange landmark line. (D) Kaplan-Meier survival curves comparing the OS of individuals in the atezolizumab arm of IMvigor211 and IMvigor210 after a defined landmark. Tick marks show censoring events. GI = gastrointestinal.
Fig. 1. Low-grade dermatological irAEs in patients receiving atezolizumab are associated with longer OS. (A) Rate of irAEs, aggregated by system- and organ-based classification, across trials. Only irAE categories with occurrence rates >5% are shown. Low = grade 1 or 2 (orange stacking bar); High = grade 3, 4, or 5 (gray stacking bar). (B) Hazard ratios (HRs) with 95% CIs are shown as thick lines, comparing OS of individuals that experienced low-grade irAEs to those that did not experience irAE of a given classification. Individuals that experienced a high-grade irAE of the given classification were excluded from the analysis. A time-dependent covariate in a Cox proportional hazards model was used to estimate the HRs (see Methods). (C) Distribution of time to first skin irAE in days across trials. Ninety percent of patients that experienced skin irAEs lie to the left of the orange landmark line. (D) Kaplan-Meier survival curves comparing the OS of individuals in the atezolizumab arm of IMvigor211 and IMvigor210 after a defined landmark. Tick marks show censoring events. GI = gastrointestinal.CC BY-NC-ND · PubMed Central
Fig. 2. Polygenic risk for skin autoimmunity is associated with the occurrence of dermatological irAEs and OS in the atezolizumab arm of IMvigor211. (A) PRSs were computed for each individual with whole-genome germline sequencing data in IMvigor211 for dermatological autoimmune diseases: AD, PSO, and VIT. PRSs were constructed for 6 P value cutoffs (see SI Appendix, Table S2 and Methods). (B) Negative log10 P values for a given PRS testing for association with occurrence of skin irAEs controlling for five genotype principal components and sex by logistic regression. Orange circles show associations that were significant at an FDR of 10%. Gray circles did not meet statistical significance. (C) Odds ratios and 95% CIs were estimated for PRSs and skin irAE occurrence for PRSs that met a significance cutoff of FDR 10%. ORs are expressed in per-unit change of a normalized PRS. GWAS P value cutoff indicated within parentheses. (D) Negative log10 P values for a given GWAS and P value cutoff PRS testing for association with OS using a Cox proportional hazards model controlling for five genotype principal components and baseline clinical factors (see Methods). (E) Adjusted HRs and 95% CIs for PRS and OS associations are shown, using significance cutoff of 10% FDR. HRs are expressed in unit change of a normalized PRS. IC = Immunochip; T-eff = CD8 T-effector gene expression signature score; IC IHC = PD-L1 expression on immune cells; TC IHC = PD-L1 expression on tumor cells.
Fig. 2. Polygenic risk for skin autoimmunity is associated with the occurrence of dermatological irAEs and OS in the atezolizumab arm of IMvigor211. (A) PRSs were computed for each individual with whole-genome germline sequencing data in IMvigor211 for dermatological autoimmune diseases: AD, PSO, and VIT. PRSs were constructed for 6 P value cutoffs (see SI Appendix, Table S2 and Methods). (B) Negative log10 P values for a given PRS testing for association with occurrence of skin irAEs controlling for five genotype principal components and sex by logistic regression. Orange circles show associations that were significant at an FDR of 10%. Gray circles did not meet statistical significance. (C) Odds ratios and 95% CIs were estimated for PRSs and skin irAE occurrence for PRSs that met a significance cutoff of FDR 10%. ORs are expressed in per-unit change of a normalized PRS. GWAS P value cutoff indicated within parentheses. (D) Negative log10 P values for a given GWAS and P value cutoff PRS testing for association with OS using a Cox proportional hazards model controlling for five genotype principal components and baseline clinical factors (see Methods). (E) Adjusted HRs and 95% CIs for PRS and OS associations are shown, using significance cutoff of 10% FDR. HRs are expressed in unit change of a normalized PRS. IC = Immunochip; T-eff = CD8 T-effector gene expression signature score; IC IHC = PD-L1 expression on immune cells; TC IHC = PD-L1 expression on tumor cells.CC BY-NC-ND · PubMed Central
Fig. 3. PRSs for dermatological autoimmunity are informative of the effect of treatment in IMvigor211. (A) Negative log10 P values for a given PRS testing for a statistically significant trial arm by PRS/tumor factor interaction using a Cox proportional hazards model for OS, controlling also for five genotype PCs, sex, and clinical covariates (see Methods). Orange circles designate PRS and trial arm interaction terms that were significant at an FDR of 10%. Gray circles indicate values that did not meet statistical significance. (B) HRs and 95% CI for Cox proportional hazard models are shown, comparing trial arms in subgroups of high and low risk for PRSs that showed the strongest trial arm by PRSs interaction. HRs were adjusted for baseline clinical covariates, genotype PCs, and sex (see Methods). High- and low-risk groups were defined by splitting the population on the median. Respective GWAS P value cutoff of the corresponding PRS is indicated in parentheses. (C) Spearman’s rank correlation between PRSs and tumor factors across individuals in IMvigor211. Rank correlations with P ≥ 0.05 are labeled ns. T-eff = CD8 T-effector gene expression signature score; IC PD-L1 = immune cell PD-L1 expression by IHC; TC PD-L1 = tumor cell PD-L1 expression by IHC. (D) HRs and 95% CIs from Cox proportional hazard models are shown comparing OS of subgroups of high and low risk for PRSs within each trial arm. atezo = atezolizumab; chemo = chemotherapy.
Fig. 3. PRSs for dermatological autoimmunity are informative of the effect of treatment in IMvigor211. (A) Negative log10 P values for a given PRS testing for a statistically significant trial arm by PRS/tumor factor interaction using a Cox proportional hazards model for OS, controlling also for five genotype PCs, sex, and clinical covariates (see Methods). Orange circles designate PRS and trial arm interaction terms that were significant at an FDR of 10%. Gray circles indicate values that did not meet statistical significance. (B) HRs and 95% CI for Cox proportional hazard models are shown, comparing trial arms in subgroups of high and low risk for PRSs that showed the strongest trial arm by PRSs interaction. HRs were adjusted for baseline clinical covariates, genotype PCs, and sex (see Methods). High- and low-risk groups were defined by splitting the population on the median. Respective GWAS P value cutoff of the corresponding PRS is indicated in parentheses. (C) Spearman’s rank correlation between PRSs and tumor factors across individuals in IMvigor211. Rank correlations with P ≥ 0.05 are labeled ns. T-eff = CD8 T-effector gene expression signature score; IC PD-L1 = immune cell PD-L1 expression by IHC; TC PD-L1 = tumor cell PD-L1 expression by IHC. (D) HRs and 95% CIs from Cox proportional hazard models are shown comparing OS of subgroups of high and low risk for PRSs within each trial arm. atezo = atezolizumab; chemo = chemotherapy.CC BY-NC-ND · PubMed Central
Fig. 4. Polygenic risk for PSO is informative of the effect of treatment in specific tumor immune contexts. HR and 95% CI compare the trial arms. Patients are stratified by of high or low tumor factor across the two columns. Within each row, patients are stratified by high or low risk for PSO using the PSO/IC PRS at a GWAS P value cutoff of 0.1. “All” designates no PRS stratification. HRs were adjusted for RNA-seq batch effects, baseline clinical covariates, genotype PCs, and sex (see Methods). High or low PRS groups and high or low tumor gene expression groups were defined by splitting the population on their median values, respectively. IC0-3 designates increasing levels of IC staining of PD-L1 by IHC. Only tumor factors and genes that met defined filtering criteria (SI Appendix, Table S5) and were significant at an FDR of 10% are shown here (see SI Appendix, Table S6 and Fig. S13 for all tested PRSs, genes, and tumor factors).
Fig. 4. Polygenic risk for PSO is informative of the effect of treatment in specific tumor immune contexts. HR and 95% CI compare the trial arms. Patients are stratified by of high or low tumor factor across the two columns. Within each row, patients are stratified by high or low risk for PSO using the PSO/IC PRS at a GWAS P value cutoff of 0.1. “All” designates no PRS stratification. HRs were adjusted for RNA-seq batch effects, baseline clinical covariates, genotype PCs, and sex (see Methods). High or low PRS groups and high or low tumor gene expression groups were defined by splitting the population on their median values, respectively. IC0-3 designates increasing levels of IC staining of PD-L1 by IHC. Only tumor factors and genes that met defined filtering criteria (SI Appendix, Table S5) and were significant at an FDR of 10% are shown here (see SI Appendix, Table S6 and Fig. S13 for all tested PRSs, genes, and tumor factors).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 91

Metadata

Authors
Khan, Z., Di Nucci, F., Kwan, A., Hammer, C., Mariathasan, S., Rouilly, V., Carroll, J., Fontes, M., Ley Acosta, S., Guardino, E., Chen-Harris, H., Bhangale, T., Mellman, I., Rosenberg, J., Powles, T., Hunkapiller, J., Chandler, G. S., & Albert, M. L.
Affiliations
  • Genentech (US)
  • Genentech, South San Francisco, CA 94080;
  • Memorial Sloan Kettering Cancer Center (US)
  • Queen Mary University of London (GB)
Corresponding author
  • Khan, Zia
  • Mellman, Ira
  • Albert, Matthew L.
Venue
Proceedings of the National Academy of Sciences
Published
2020-05-19
Volume
117
Issue
22
Pages
12288-12294
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3026699635
Cited by
91
References
27
Citations by year
2026: 9 · 2025: 10 · 2024: 12 · 2023: 19 · 2022: 22 · 2021: 16 · 2020: 3
FWCI
5.42
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Genentech
  • National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
polygenic risk score, skin autoimmunity, immune checkpoint blockade, bladder cancer, PD-L1 blockade, atezolizumab, vitiligo, psoriasis, atopic dermatitis, immune-related adverse events, Th17 polarization, overall survival, germline mutations
MeSH terms
Urinary Bladder Neoplasms, Humans, Skin, Cohort Studies, Autoimmunity, Multifactorial Inheritance, Th17 Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. https://app.cochat.ai/papers/10.1073/pnas.1922867117
The paper
Khan, Z., Di Nucci, F., Kwan, A., Hammer, C., Mariathasan, S., Rouilly, V., Carroll, J., Fontes, M., Ley Acosta, S., Guardino, E., Chen-Harris, H., Bhangale, T., Mellman, I., Rosenberg, J., Powles, T., Hunkapiller, J., Chandler, G. S., & Albert, M. L. (2020). Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1922867117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.